FDA Grants Philip Morris License to Market Zyn as Reduced-Harm Alternative

Event Summary

On July 1, the FDA authorized Philip Morris to market 20 ZYN nicotine pouches with claims of reduced disease risk after a scientific review. On July 3, the FDA classified Insulet's correction to its Omnipod systems as a Class I recall due to a cannula defect. On July 6, the FDA classified Insulet's Omnipod recall as Class I after reports of insulin under-delivery linked to serious injuries.